This technology is a de novo-designed peptide modulator that selectively inhibits late sodium current in cardiac sodium channels to treat arrhythmias and heart failure without affecting normal channel function.
Increased late sodium current is a driver of cardiac conditions like Long QT Syndrome Type 3 (LQT3) and heart failure, but existing drugs often lack specificity and have significant side effects. Current treatments for cardiac arrhythmias often rely on small-molecule inhibitors that block both peak and late sodium currents, which can lead to off-target effects and conduction disturbances. There is a critical need for a therapeutic agent that can precisely target the pathogenic late current without disrupting the peak current required for normal cardiac excitability.
This technology introduces "ELIXIR" (Engineered Late-current Inhibitor by Inactivation-gate Release), a computationally designed peptide that selectively inhibits the late sodium current of the cardiac voltage-gated sodium channel, Nav1.5. ELIXIR binds to the channel's C-terminal domain to stabilize the closed state, mechanically enhance the native inactivation process. Unlike traditional blockers, this approach allows the peptide to preferentially inhibit pathological channels while preserving the activity of normally functioning channels, which are essential for the cardiac action potential.
This technology has been validated in patient-derived iPSC-cardiomyocytes and transgenic mouse models.
Patent Pending
IR CU24196
Licensing Contact: Kristin Neuman